Pharmaceutical News

RSS

Scientists develop new genetic platform that yields novel antibiotic from ocean bacteria

Scientists at the University of California, San Diego have developed a new genetic platform that allows efficient production of naturally occurring molecules, and have used it to produce a novel antibiotic compound.

23 Jan 2014

Scientists give cautious welcome for new types of drug intended for use in place of antibiotics

New types of drug intended for use in place of antibiotics have been given a cautious welcome by scientists.

23 Jan 2014

ICR, Nuevolution and CRT partner to identify novel drug candidates for cancer treatment

The Institute of Cancer Research, London, Cancer Research Technology, London and Nuevolution A/S, Copenhagen have entered into a drug discovery collaboration to identify novel lead candidates for cancer treatment.

23 Jan 2014

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time.

22 Jan 2014

Xpert MTB/RIF test quickly detects TB and resistance to rifampicin

A second systematic review of a diagnostic test for tuberculosis (TB) endorsed by the World Health Organisation (WHO), has confirmed the accuracy of the test. The updated review assessing the accuracy of Xpert MTB/RIF includes new studies published since the original Cochrane Review was published in January last year.

22 Jan 2014

FSMB joins with partners to educate health care professionals on safe prescribing of opioid analgesics

The Federation of State Medical Boards (FSMB) and FSMB Foundation are collaborating with several partners to provide state medical boards with resources to educate health care professionals on the safe and responsible prescribing of extended-release (ER) and long-acting (LA) opioid analgesics for patients with chronic pain.

22 Jan 2014

Potentially preventable deficiencies account for significant delays in approval of new drugs by FDA

Several potentially preventable deficiencies, including failure to select optimal drug doses and suitable outcome measures for a study, accounted for significant delays in the approval of new drugs by the Food and Drug Administration (FDA), according to a study in the January 22/29 issue of JAMA.

22 Jan 2014

Researchers suggest new targets may provide druggable alternatives to Ewing's Sarcoma

Ewing's Sarcoma is an aggressive pediatric cancer, most commonly caused by the improper fusion of the gene EWS with the gene FLI1. Though the cause has long been known, therapeutic targeting of this fusion has to date proven very difficult.

22 Jan 2014

Swedish study confirms H1N1 vaccinations show increased risk of narcolepsy in children, adolescents

Pandemrix is an influenza vaccination, created in 2009 to combat H1N1, known as Swine Flu. Now, a team of Swedish clinicians testing the vaccine for links to immune-related or neurological diseases have linked Pandemrix to an increased risk of narcolepsy in young adults.

21 Jan 2014

Study provides insight into physician recommendations to improve HPV vaccination

The risk of developing cervical cancer can be significantly decreased through human papillomavirus vaccination. Despite calls from leading health and professional organizations for universal vaccination for girls ages 11 and 12, the most recently published national data indicate that only 14.5 percent of 11- and 12-year-old girls have received at least one dose of the HPV vaccine and 3 percent have completed the three-dose series. A new Moffitt Cancer Center study provides insight into physician recommendations, one important factor that may contribute to these low levels of uptake.

21 Jan 2014

Role of folate in development, progression of breast cancer highly controversial

Folic acid supplements at levels consumed by breast cancer patients and survivors in North America promoted the growth of existing breast cancer in rats, new research found.

21 Jan 2014

It Works! Global announces launch of first chewable dietary supplement

It Works! Global, a wellness products and lifestyle company, announced the launch of Greens Chew, a dietary supplement for antioxidant and prebiotic support.

21 Jan 2014

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients.

21 Jan 2014

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

ViiV Healthcare today announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.

21 Jan 2014

Scientists develop new class of molecules that provide new way to attack bacteria resistant to antibiotics

As concerns about bacterial resistance to antibiotics grow, researchers are racing to find new kinds of drugs to replace ones that are no longer effective. One promising new class of molecules called acyldepsipeptides - ADEPs - kills bacteria in a way that no marketed antibacterial drug does - by altering the pathway through which cells rid themselves of harmful proteins.

20 Jan 2014

Strontium should no longer be used for osteoporosis treatment, warns European Agency

All persons taking strontium supplements are warned that significant risks have been identified. Strontium drugs are not approved for treatment of osteoporosis in the United States. Now, the Risk Assessment Committee of the European Medicines Agency recommended that strontium should no longer be used to treat osteoporosis in Europe. The drugs Protelos/Osseor were specifically named as brand names for strontium ranelate.

19 Jan 2014

$Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL$

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.

18 Jan 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Sovaldi (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C infection in adults, in combination with other antiviral agents (ribavirin and pegylated interferon alpha (peg-IFN)).

18 Jan 2014

FDA approves New Drug Application for PENNSA 2%

Mallinckrodt today announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s).

17 Jan 2014

Pharmaceutical News

Scientists develop new genetic platform that yields novel antibiotic from ocean bacteria

Scientists give cautious welcome for new types of drug intended for use in place of antibiotics

ICR, Nuevolution and CRT partner to identify novel drug candidates for cancer treatment

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

Xpert MTB/RIF test quickly detects TB and resistance to rifampicin

FSMB joins with partners to educate health care professionals on safe prescribing of opioid analgesics

Potentially preventable deficiencies account for significant delays in approval of new drugs by FDA

Researchers suggest new targets may provide druggable alternatives to Ewing's Sarcoma

Swedish study confirms H1N1 vaccinations show increased risk of narcolepsy in children, adolescents

Study provides insight into physician recommendations to improve HPV vaccination

Role of folate in development, progression of breast cancer highly controversial

It Works! Global announces launch of first chewable dietary supplement

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

Scientists develop new class of molecules that provide new way to attack bacteria resistant to antibiotics

Strontium should no longer be used for osteoporosis treatment, warns European Agency

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

FDA approves New Drug Application for PENNSA 2%

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News